A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Authors :: Ades L
Guerci-Bresler A
Cony-Makhoul P
Legros L
Sebert M
Braun T
Delaunay J
Desseaux K
Chevret S
Fenaux P
Source :: Haematologica [Haematologica] 2019 Apr; Vol. 104 (4), pp. e131-e133. Date of Electronic Publication: 2018 Oct 31.
Publication Year :: 2019

Subjects :: Adolescent
Adult
Aged
Azacitidine adverse effects
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes blood
Myelodysplastic Syndromes pathology
Risk Factors
Azacitidine administration & dosage
Myelodysplastic Syndromes drug therapy

Full Text Access

Tools